期待が高まる核医学治療 ― 日本でのLu-PSMA療法の現状とこれから・第27回がんチューブ専門医ダイレクトライブ20260405

期待が高まる核医学治療 ― 日本でのLu-PSMA療法の現状とこれから・第27回がんチューブ専門医ダイレクトライブ20260405

🎙 がんチューブ (一般社団法人日本癌治療学会) 👥 5K 📅 April 5, 2026 ⏱ 120 min 👁 4K 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

Lu-PSMAprostate cancertheranosticsnuclear medicineJapan

Summary

This video is a live broadcast from the Japan Cancer Therapy Society, featuring Dr. Kotaro Suzuki from Kobe University, who delivers a keynote lecture on the current state and future of Lu-PSMA therapy for prostate cancer in Japan. The lecture covers the concept of theranostics, combining diagnosis and therapy using PSMA-targeted agents. It explains the mechanism of PSMA PET imaging and Lu-177 PSMA therapy, highlighting the clinical trial data (PSMAfore and VISION) that led to its approval. The discussion also addresses the challenges of treatment capacity, the need for specialized facilities, radiation safety, and patient selection criteria. The second half includes a Q&A session with a prostate cancer survivor and the audience, covering topics such as genetic testing, differences between nuclear medicine and external beam radiation, and the future of alpha-emitting therapies. The video provides a comprehensive overview for both patients and healthcare professionals, emphasizing the importance of early detection and the potential of this innovative treatment.

157 words

Critical Evaluation

Value of the Information & Strength of the Argument

The video provides valuable information on Lu-PSMA therapy, including its mechanism, clinical efficacy, and practical considerations. The argumentation is solid, based on clinical trial data and expert experience. The speaker clearly explains complex concepts, such as theranostics and PSMA targeting, making them accessible. The discussion of capacity issues and patient selection adds practical value. The Q&A section addresses common patient concerns, enhancing the video’s utility.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with references to clinical trials (PSMAfore, VISION) and national action plans. The speaker is a specialist from a leading university hospital, lending credibility. The title accurately reflects the content. The video does not cite specific sources in the description, but the information is consistent with current medical literature. The presence of a promotional segment for the patient support group ‘FACE’ is noted, but it does not detract from the scientific content.

156 words

Title / Content Match

The title accurately reflects the content, focusing on the current status and future of Lu-PSMA therapy in Japan.

Quality & Reliability

8/10

The video features a specialist in urology and nuclear medicine from Kobe University, providing a detailed and balanced overview of Lu-PSMA therapy, including clinical trial data, capacity issues, and practical management. The content is consistent with current medical knowledge, but it is primarily an expert opinion and educational lecture rather than a systematic review or original study.

Chapters

Contribution & Novelties

The video provides an up-to-date overview of Lu-PSMA therapy in Japan, including recent approval and implementation challenges. It offers practical insights into patient selection and radiation safety. The discussion of capacity issues and the need for infrastructure expansion is particularly relevant. For further exploration, consider the following:

94 words

Radar Profile

The radar profile shows high scores in information quantity, quality, and reliability, with a slightly lower technical level, indicating a well-balanced educational content suitable for a broad audience.

Reliability 8/10